Top Market Research Companies in South Korea (2026 Guide)

South Korea is a strategically distinct pharmaceutical market, with a domestic pharmaceutical market estimated at approximately KRW 30 trillion in 2026. Commercial success in South Korea depends on navigating MFDS regulatory approval, HIRA pharmacoeconomic evaluation, and NHIS positive list coverage decisions — while meeting the evidence standards applied by NECA's independent HTA in positive list assessment decisions.

South Korean pharmaceutical market research in 2026 is shaped by three defining dynamics:

• HIRA positive list pharmacoeconomic rigour: HIRA applies rigorous pharmacoeconomic criteria — including cost-effectiveness modelling, clinical comparative evidence, and budget-impact analysis — to positive list coverage applications. NECA provides independent HTA. Market researchers must design evidence aligned to HIRA and NECA methodology rather than simply adapting PBAC, NICE, or CADTH submission frameworks.
• MFDS and HIRA/NHIS sequencing: MFDS grants marketing authorisation independently — HIRA then evaluates positive list coverage separately. The sequential nature creates a period requiring manufacturer-funded access programs and pre-submission market research to optimise HIRA evidence packages and NHIS price negotiation strategy.
• Korea Big 5 hospital concentration: Korea's Big 5 hospitals (SNUH, Samsung Medical Center, Asan Medical Center, Severance Hospital, Seoul St. Mary Hospital) concentrate the country's most influential KOLs and set national clinical practice standards. Hospital formulary committee decisions at Big 5 hospitals, alongside KSMO, KSH, KCS, and KRA specialist society networks, form the key secondary audiences requiring dedicated Korean market research.

South Korean KOL mapping requires tracking influence across Korea's distinctive Big 5 hospital landscape. Seoul National University Hospital (SNUH) holds the strongest national guideline influence and academic publication prominence in oncology, haematology, cardiovascular, and transplant; Samsung Medical Center (SMC) combines strong oncology and cardiology academic output with large clinical trial enrolment; Asan Medical Center is Korea's largest hospital by patient volume with strong oncology and rare disease KOL networks; Severance Hospital (Yonsei University) leads in immunology, rheumatology, and internal medicine; and Seoul St. Mary Hospital (Catholic University of Korea) is a leading centre in haematology and bone marrow transplantation. Effective Korean KOL mapping segments influence by hospital, specialist society, therapy area, and HIRA advisory involvement.

South Korean payer research requires access to HIRA pharmacoeconomic evaluators, NHIS positive list decision-makers, and NECA health economists — the most commercially important respondents in Korean pharmaceutical research. Payer interviews cover HIRA positive list evidence requirements, NHIS budget constraints, cost-effectiveness evidence expectations, and NECA HTA assessment criteria. BioNixus conducts national HIRA/NHIS payer research as dedicated payer research programs.

BioNixus conducts KOL mapping and payer research across South Korea in oncology, cardiovascular, immunology, rare disease, metabolic, and other specialty areas. See our South Korea pharmaceutical market research guide and top healthcare market research companies in South Korea for details.